Display options
Cite
Tadić A, Rujescu D, Müller MJ, et al. Association analysis between variants of the interleukin-1beta and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression. Neuropsychiatr Dis Treat. 2008;4(1):269-76doi: 10.2147/ndt.s2262.
Tadić, A., Rujescu, D., Müller, M. J., Kohnen, R., Stassen, H. H., Szegedi, A., & Dahmen, N. (2008). Association analysis between variants of the interleukin-1beta and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression. Neuropsychiatric disease and treatment, 4(1), 269-76. https://doi.org/10.2147/ndt.s2262
Tadić, André, et al. "Association analysis between variants of the interleukin-1beta and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression." Neuropsychiatric disease and treatment vol. 4,1 (2008): 269-76. doi: https://doi.org/10.2147/ndt.s2262
Tadić A, Rujescu D, Müller MJ, Kohnen R, Stassen HH, Szegedi A, Dahmen N. Association analysis between variants of the interleukin-1beta and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression. Neuropsychiatr Dis Treat. 2008 Feb;4(1):269-76. doi: 10.2147/ndt.s2262. PMID: 18728809; PMCID: PMC2515903.
Copy Download .nbib Format: NLM
Share it on

Neuropsychiatr Dis Treat. 2008 Feb;4(1):269-76. doi: 10.2147/ndt.s2262.

Association analysis between variants of the interleukin-1beta and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression.

Neuropsychiatric disease and treatment

André Tadić, Dan Rujescu, Matthias J Müller, Ralf Kohnen, Hans H Stassen, Armin Szegedi, Norbert Dahmen

Affiliations

  1. Department of Psychiatry, University of Mainz Germany.

PMID: 18728809 PMCID: PMC2515903 DOI: 10.2147/ndt.s2262

Abstract

This study investigated the possible association of the interleukin-1 beta (IL-1beta) C-511T promoter polymorphism and the interleukin-1 receptor antagonist (IL-1Ra) (86bp)(n) variable number of tandem repeats (VNTR) polymorphism with antidepressant response to paroxetine and mirtazapine treatment. The study group consisted of 101 patients suffering from DSM-IV major depression participating in a randomized double-blind controlled clinical trial. Patients homozygous for the IL-1beta-511T allele had a significantly faster and more pronounced response to paroxetine treatment than IL-1beta-511C allele carriers. No association was found for the IL-1beta C-511T polymorphism with mirtazapine treatment response. The IL-1Ra VNTR showed neither an association with paroxetine nor with mirtazapine treatment response. Our results provide further suggestive evidence that time course of response and antidepressant efficacy of paroxetine, but not of mirtazapine, is influenced in a clinically relevant manner by the IL-1beta C-511T gene variant. Our data do not support the hypothesis that the IL-1Ra (86bp)(n) VNTR affects antidepressant treatment response to paroxetine or mirtazapine. An independent replication of our finding is needed. If replicated, the IL-1beta C-511T promoter polymorphism could be considered useful for prospective confirmatory pharmacogenetic trials in patients with major depression.

Keywords: antidepressive agents; genetic polymorphisms; interleukin-1 beta; interleukin-1 receptor antagonist; major depression; treatment outcome

References

  1. Am J Med Genet B Neuropsychiatr Genet. 2007 Apr 5;144B(3):325-31 - PubMed
  2. Eur J Immunol. 1998 Aug;28(8):2598-602 - PubMed
  3. Mol Psychiatry. 1999 Mar;4(2):182-8 - PubMed
  4. Acta Psychiatr Scand. 2001 Mar;103(3):226-8 - PubMed
  5. Brain Res. 1995 Oct 16;695(2):279-82 - PubMed
  6. Psychoneuroendocrinology. 2004 Jul;29(6):778-90 - PubMed
  7. Neuropsychopharmacology. 2001 May;24(5):531-44 - PubMed
  8. Exp Physiol. 2007 Sep;92(5):807-11 - PubMed
  9. Hum Genet. 1993 May;91(4):403-4 - PubMed
  10. Mol Psychiatry. 1999 Jul;4(4):317-27 - PubMed
  11. Pol J Pharmacol. 2000 May-Jun;52(3):237-41 - PubMed
  12. Trends Immunol. 2006 Jan;27(1):24-31 - PubMed
  13. Brain Behav Immun. 2002 Oct;16(5):569-74 - PubMed
  14. Neuropsychopharmacology. 2003 Jun;28(6):1182-5 - PubMed
  15. Brain Res. 1997 Jul 4;761(2):225-35 - PubMed
  16. Pharmacogenomics J. 2005;5(1):49-53 - PubMed
  17. Gen Hosp Psychiatry. 2003 Nov-Dec;25(6):495-6 - PubMed
  18. J Affect Disord. 2005 Aug;87(2-3):305-11 - PubMed
  19. J Clin Psychiatry. 2000 Sep;61(9):656-63 - PubMed
  20. Neuroscience. 1999;88(3):823-36 - PubMed
  21. J Biopharm Stat. 2001 Feb-May;11(1-2):9-21 - PubMed
  22. Neuroscience. 2005;135(3):659-78 - PubMed
  23. Genomics. 1994 Jan 15;19(2):382-4 - PubMed
  24. Prog Neuropsychopharmacol Biol Psychiatry. 2005 Feb;29(2):201-17 - PubMed
  25. Adv Exp Med Biol. 1999;461:117-27 - PubMed
  26. CNS Drug Rev. 2001 Fall;7(3):249-64 - PubMed
  27. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Oct 1;31(7):1370-7 - PubMed
  28. Int J Neuropsychopharmacol. 2006 Feb;9(1):27-35 - PubMed
  29. Pharmacopsychiatry. 2002 Nov;35(6):220-5 - PubMed
  30. Brain Behav Immun. 2004 May;18(3):221-2 - PubMed
  31. Hum Mol Genet. 1992 Sep;1(6):450 - PubMed
  32. Adv Exp Med Biol. 1999;461:199-233 - PubMed
  33. J Neurosci. 1995 Apr;15(4):2920-34 - PubMed
  34. Neuropsychopharmacology. 2006 Oct;31(10):2121-31 - PubMed
  35. Nature. 2000 Mar 23;404(6776):398-402 - PubMed
  36. Neuropsychobiology. 2001;43(2):59-62 - PubMed
  37. Eur J Clin Invest. 1992 Jun;22(6):396-402 - PubMed
  38. Int J Neuropsychopharmacol. 2002 Dec;5(4):401-12 - PubMed
  39. Acta Psychiatr Scand. 1998 Apr;97(4):309-13 - PubMed
  40. Am J Psychiatry. 2005 Jan;162(1):175-7 - PubMed
  41. Biochem Biophys Res Commun. 1995 Nov 13;216(2):560-7 - PubMed
  42. J Affect Disord. 2001 Mar;63(1-3):93-102 - PubMed
  43. Neurosci Lett. 1996 Sep 13;215(3):201-4 - PubMed
  44. Neuropsychobiology. 1999 Nov;40(4):171-6 - PubMed
  45. J Biopharm Stat. 2003 May;13(2):179-90 - PubMed

Publication Types